Cinda Bio-Innovative Oncology Drug Dabershu ® Joint IBI305 clinical study for first-line hepatocellular carcinoma completes first patient administration

Today, Cinda Bio
Pharmaceutical(http://(Hong Kong Stock Exchange Code: 01801) announced that the innovative oncologydrug(http://Dabo shu ® (recombinant whole human source anti-PD-1 monoclonal antibody, English trademark: Tyvy) t®: Sindilli mono-anti-injection) joint lycinized anti-VEGF humanized monoclonal antibody injection (IBI305) for first-line hepatocellular carcinoma clinical research (ORIENT-32) to complete the first patient administrationThe ORIENT-32 study is a randomized, open, multicenter, II/III clinical study conducted in China to assess the effectiveness and safety of Theabshu ® and the effectiveness and safety of the combined IBI305 comparable Isofinib for first-line treatment of patients with advanced hepatocellular carcinomaThe project is based on a phase Ib clinical study that evaluates Damershu ® treatment of advanced hepatocellular carcinoma subjectsAbout Daboshu ® (Sindili mono-injection)Daboshu ® (Sindili mono-injection) is an innovative biopharmaceutical of international quality developed by Sinda Biopharma and Lilly Pharmaceuticals in ChinaCinda Bio is currently conducting clinical research on Sindy Li monoantigen injections in the United StatesDabershu ® (Sindyli monoantigen) is a human immunoglobulin G4 (IgG4) monoclonal antibody that specifically binds to the PD-1 molecule on the surface of The T cell, thus blocking the PD-1/programmed death receptor ligand 1 (Programme Cell Mortal-1 Ligand-1, PD-L1) pathway that reactivates the antitumor activity of lymphatic cellsDabershu ® (Sindili mono-injection) is an international quality Of China's innovative PD-1 inhibitors, its listing application has been formally approved by the NationalDrug(http://Regulatory Authority, the first indication approved is recurrent/difficult to treat classic Hodgkin's lymphoma More than 20 clinical studies (seven of which are registered clinical trial sympathising (http:// ) are currently under way to explore the anti-tumor effects of SindyLi monoantigen on other solid tumors 　　About IBI305 (Bevalabethan anti-biosimilars) IBI305 biosimilars of the Bevalados isore, also known as recombinant anti-VEGF humanized monoclonal antibody injections VEGF is an important factor in angiogenesis, over-pathological expression in endothelial cells of most human tumors Anti-VEGF antibodies, which can be highly affinityally selectively bind to VEGF, block the conduction of signaling pathways such as PI3K-Akt/PKB and Ras-Raf-MEK-ERK by blocking VEGF binding to receptors on the surface of their vascular endothelial cells In order to inhibit the growth, proliferation and migration of vascular endothelial cells and the rebirth of blood vessels, reduce vascular permeability, block the blood supply of tumor tissue (http:// , inhibit the proliferation and metastasis of tumor cells, induce tumor cell apoptosis, so as to achieve anti-tumor treatment effect On January 29, 2019, the State Drug Administration (NMPA) accepted The New Drug (http:// listing application (NDA) for IBI305